Self-suggestion.

The earnings report showed that both revenue and EPS exceeded expectations, providing temporary relief. With the upward revision of the full-year revenue forecast, there is some reassurance.

It has been about two years since I first acquired shares, but LLY is a large company investing not only in diabetes and obesity drugs but also in treatments for dementia, cancer, and various other diseases. Moving forward, they will partner with NVDA to aggressively pursue AI monetization in pharmaceutical development.

Although the stock price has been struggling to grow, patience is key to profiting from stocks. It’s important to hold on tightly to quality stocks. (A reminder to my nervous self 💦)

Do not sell. Do not sell. Do not sell.